Abstract
Cirrhosis remains a major cause of liver-related mortality worldwide. The transition from compensated to decompensated disease, marked by complications such as ascites, hepatic encephalopathy, or variceal hemorrhage represents a critical shift in prognosis and survival. Clinically significant portal hypertension (CSPH) is the primary driver of this progression, making portal pressure reduction a central therapeutic target.
For decades, non-selective beta-blockers (NSBBs) such as propranolol and nadolol have been used to lower portal pressure by reducing cardiac output and splanchnic blood flow. Carvedilol has recently emerged as a promising alternative because, in addition to β-adrenergic blockade, it also antagonizes α1 receptors, leading to intrahepatic vasodilation and greater reductions in hepatic venous pressure gradient.
This commentary discusses the findings of a recent propensity score matched cohort study by Almasri et al., which compared carvedilol and propranolol in patients with compensated cirrhosis using a large real-world U.S. database. The study demonstrated a lower incidence of hepatic decompensation among patients receiving carvedilol and suggested a modest reduction in long-term mortality, although hospitalization rates were higher.
These findings support a growing body of evidence favoring carvedilol as a first-line agent for portal hypertension. While observational data are increasingly compelling, randomized trials powered for clinical outcomes are still needed to definitively establish the optimal beta-blocker strategy in compensated cirrhosis.
Keywords
Cirrhosis, Portal hypertension, Carvedilol, Non-selective Beta-blockers, Hepatic decompensation